Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Liposomal Doxorubicin in Soft Tissue Sarcoma (ALTER-S001)
NCT03880695Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in soft tissue sarcoma (STS), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03880695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880695.